This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Canopy Growth Corporation (CGC) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $7.13, moving -1.25% from the previous trading session.
Canopy Growth Corporation (CGC) Advances But Underperforms Market: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, Canopy Growth Corporation (CGC) stood at $6.50, denoting a +0.31% change from the preceding trading day.
Canopy Growth Corporation (CGC) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
Canopy Growth Corporation (CGC) reachead $6.67 at the closing of the latest trading day, reflecting a +0.6% change compared to its last close.
Canopy Growth Corporation (CGC) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Canopy Growth (CGC) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Canopy Growth Corporation (CGC) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Canopy Growth (CGC) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year?
by Zacks Equity Research
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Canopy Growth Corporation (CGC) have performed compared to their sector so far this year.
Canopy Growth Corporation (CGC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Canopy Growth (CGC) delivered earnings and revenue surprises of 15.15% and 2.43%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Canopy Growth (CGC) Ahead of Q4 Earnings?
by Moumi Mondal
Canopy Growth's (CGC) rightsized cannabis-focused business is a major foundation for growth.
Canopy Growth Corporation (CGC) Rises Higher Than Market: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, Canopy Growth Corporation (CGC) stood at $9.18, denoting a +0.77% change from the preceding trading day.
Will Canopy Growth Corporation (CGC) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Canopy Growth (CGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medtronic (MDT) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of 0.69% and 1.80%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Canopy Growth Corporation (CGC) concluded the recent trading session at $10.85, signifying a -1.36% move from its prior day's close.
Investors Heavily Search Canopy Growth Corporation (CGC): Here is What You Need to Know
by Zacks Equity Research
Canopy Growth (CGC) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Strength Seen in Canopy Growth (CGC): Can Its 11.0% Jump Turn into More Strength?
by Zacks Equity Research
Canopy Growth (CGC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Canopy Growth Corporation (CGC) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
The latest trading day saw Canopy Growth Corporation (CGC) settling at $10.24, representing a -0.97% change from its previous close.
Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Boston Scientific (BSX) and Canopy Growth Corporation (CGC) have performed compared to their sector so far this year.
Do Options Traders Know Something About Canopy Growth (CGC) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Canopy Growth (CGC) stock based on the movements in the options market lately.
Canopy Growth Corporation (CGC) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $4.79, moving -0.83% from the previous trading session.
ResMed (RMD) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of 3.87% and 0.46%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Canopy Growth Corporation (CGC) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) reachead $4.41 at the closing of the latest trading day, reflecting a +0.92% change compared to its last close.
Canopy Growth Corporation (CGC) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
In the most recent trading session, Canopy Growth Corporation (CGC) closed at $4.56, indicating a -0.87% shift from the previous trading day.
Canopy Growth Corporation (CGC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
The latest trading day saw Canopy Growth Corporation (CGC) settling at $4.86, representing a +1.46% change from its previous close.
Zacks Market Edge Highlights: Canopy Growth, Tilray Brands, Constellation Brands, Innovative Industrial Properties and Jazz Pharmaceuticals
by Zacks Equity Research
Canopy Growth, Tilray Brands, Constellation Brands, Innovative Industrial Properties and Jazz Pharmaceuticals are part of the Zacks Market Edge blog.
Pot Stocks: Values or Traps?
by Tracey Ryniec
Pot stocks used to be hot but many have plunged over the last 2 years. Are there deals?
Canopy Growth Corporation (CGC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Canopy Growth Corporation (CGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.